Document is current
Any future updates will be listed below
-
Authors
Bojsen-Møller, Kirstine Nyvold https://orcid.org/0000-0003-1962-5302
Svane, Maria Saur https://orcid.org/0000-0002-7345-4471
Martinussen, Christoffer
Dirksen, Carsten https://orcid.org/0000-0002-2173-6469
Jørgensen, Nils Bruun
Jensen, Jens-Erik Beck
Jensen, Christian Zinck
Torekov, Signe Sørensen https://orcid.org/0000-0001-6779-0252
Kristiansen, Viggo Bjerregaard
Rehfeld, Jens Frederik
Bork-Jensen, Jette
Grarup, Niels https://orcid.org/0000-0001-5526-1070
Hansen, Torben https://orcid.org/0000-0001-8748-3831
Hartmann, Bolette
Holst, Jens Juul https://orcid.org/0000-0001-6853-3805
Madsbad, Sten
- License Information
-
More Information
Article History
Received: 2 February 2023
Revised: 11 August 2023
Accepted: 17 August 2023
First Online: 31 August 2023
Competing interests
: CM has received support from Novo Nordisk A/S for organizing/attending meetings. JEBJ and SST have received research grants and lecture fees from Novo Nordisk A/S. CD has served as advisor for Novo Nordisk A/S and AstraZeneca and received lecture fees from Novo Nordisk A/S. NBJ has served on advisory panels and in educational programs from Novo Nordisk A/S, has received research support from Boehringer Ingelheim Denmark. In addition, NBJ reports having taken a position with Novo Nordisk A/S as of March 2023. The remaining authors have no competing interests related to this study.
